<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00290771</url>
  </required_header>
  <id_info>
    <org_study_id>CSTI571H2201</org_study_id>
    <secondary_id>CSTI571H2202</secondary_id>
    <nct_id>NCT00290771</nct_id>
    <nct_alias>NCT00292149</nct_alias>
  </id_info>
  <brief_title>Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)</brief_title>
  <official_title>A Phase II, Open-label, Multicenter Study Evaluating the Efficacy of Imatinib Plus Hydroxyurea (HU) in Patients With Progressive Glioblastoma Multiforme (GBM) Receiving or Not Receiving Enzyme-inducing Anticonvulsant Drugs (EIACDs)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an investigational study to assess the objective overall response (OOR) rate
      (complete response [CR] + partial response [PR]) of imatinib mesylate and hydroxyurea
      (hydroxycarbamide) combination therapy in patients with recurrent glioblastoma multiforme
      (brain tumors). This study also evaluated the duration of tumor response (as per MacDonald
      criteria), clinical benefit, progression-free survival rate at 6 and 12 months, and the
      survival rate at 12 and 24 months.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This ClinicalTrials.gov record includes the results from two studies (Novartis protocol IDs
      CSTI571H2201 and CSTI571H2202) which were conducted separately but reported together in a
      single clinical study report. Both studies were phase II, open-label, multicenter, single-arm
      studies that evaluated the efficacy of imatinib mesylate plus hydroxyurea in subjects with
      progressive glioblastoma multiforme. The studies were identical in design with two
      exceptions: Patients in study CSTI571H2201 received a dose of imatinib 600 mg once daily and
      were not allowed concomitant use of enzyme-inducing anticonvulsant drugs (EIACDs); patients
      in study CSTI571H2202 received a dose of imatinib 500 mg twice daily and were allowed
      concomitant use of EIACDs.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy
  </why_stopped>
  <start_date>February 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With an Objective Overall Response (OOR)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Objective Overall Response (OOR)</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Who Had Clinical Benefit</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Progression-free Survival at Months 6 and 12</measure>
    <time_frame>Months 6 and 12</time_frame>
    <description>Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients Surviving at Months 6, 12, and 24</measure>
    <time_frame>Months 6, 12, and 24</time_frame>
    <description>Patients not known to have died were censored at the time of last survival follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients With at Least 1 Adverse Event</measure>
    <time_frame>Baseline to end of study (Month 24)</time_frame>
    <description>An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>Recurrent Glioblastoma Multiforme (GBM)</condition>
  <arm_group>
    <arm_group_label>Imatinib 600 mg + hydroxyurea 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Imatinib 1000 mg + hydroxyurea 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imatinib tablets</intervention_name>
    <description>Imatinib was supplied as 100 and 400 mg tablets by Novartis.</description>
    <arm_group_label>Imatinib 600 mg + hydroxyurea 1000 mg</arm_group_label>
    <arm_group_label>Imatinib 1000 mg + hydroxyurea 1000 mg</arm_group_label>
    <other_name>Glivec®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxyurea capsules</intervention_name>
    <description>Hydroxyurea was supplied locally as 500 mg capsules.</description>
    <arm_group_label>Imatinib 600 mg + hydroxyurea 1000 mg</arm_group_label>
    <arm_group_label>Imatinib 1000 mg + hydroxyurea 1000 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Males and females ≥ 18 years old.

          -  Histologically-confirmed diagnosis of progressive primary glioblastoma multiforme
             (GBM) based on original diagnosis. Patients with prior low-grade glioma were eligible
             if histological re-assessment demonstrated transformation to GBM.

          -  No more than one prior episode of progressive disease following previously received
             surgery and/or radiation and only one prior chemotherapy exposure of either
             temozolomide (TMZ) or nitrosourea including the application of polifeprosan (Gliadel®)
             wafers.

          -  Presence of measurable disease on gadolinium-enhanced magnetic resonance imaging
             (MRI).

          -  Patients taking steroids must have been on a stable dose for ≥ 7 days.

          -  Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2.

          -  Hemoglobin ≥ 10 g/dL (or hematocrit &gt; 29%), absolute neutrophil count (ANC) &gt; 1500
             cells/L, platelets &gt; 100,000 cells/L.

          -  Serum creatinine &lt; 1.5 mg/dL, blood urea nitrogen (BUN) &lt; 25 mg/dL, serum aspartate
             aminotransferase (AST) and bilirubin &lt; 1.5 x upper limit of normal (ULN).

          -  Sexually-active male and female patients were required to use double-barrier
             contraception (oral contraceptive plus barrier contraceptive) or must have undergone
             clinically documented total hysterectomy, ovariectomy, or tubal ligation.

          -  Female patients of childbearing potential must have had a negative pregnancy test
             within 48 hours prior to start of study drug.

          -  Life expectancy ≥ 8 weeks.

          -  Signed informed consent by the patient prior to patient entry and any study procedure.

        Exclusion Criteria:

          -  Receipt of imatinib or hydroxyurea (HU) prior to study entry or receipt of any
             investigational agent within the last 6 months.

          -  Patients who had received a second course of chemotherapy or radiotherapy, unless
             given as a single localized application of radio surgery.

          -  In study STI571H2201 only, receipt of enzyme-inducing anticonvulsant drugs (EIACDs),
             eg, carbamazepine, phenobarbital, phenytoin, fosphenytoin, oxcarbazepine, or
             primidone. Previous EIACD should have been interrupted 4 weeks prior to study start.

          -  Grade ≥ 2 peripheral edema or pulmonary or pericardial effusions or ascites of any
             grade.

          -  Presence of any uncontrolled systemic infection.

          -  Patients who were not a minimum of 12 weeks from completion of conventional external
             beam radiotherapy unless:

               1. There was new radiographical enhancement outside the field of radiation, or

               2. There was new pathological confirmation of recurrent tumor, or

               3. Progressive radiographical enhancement noted on post-radiotherapy/TMZ continue to
                  worsen after an additional course of TMZ.

          -  Evidence of intra-tumor hemorrhage on pretreatment diagnostic imaging, except for
             stable post-operative Grade 1 hemorrhage, patients with an excessive risk of an
             intracranial hemorrhagic event, and patients with history of central nervous system
             (excluding post-operative Grade 1) or intraocular bleed.

          -  Patients who had undergone major surgery within 2 weeks prior to study entry or who
             had not recovered from prior major surgery, patients who had received chemotherapy
             within 4 weeks prior to study start, or who have not recovered from toxic effects of
             such therapy.

          -  Impairment of gastrointestinal function or gastrointestinal disease that could
             significantly alter the absorption of imatinib.

          -  Patients taking warfarin sodium.

          -  Known history of human immunodeficiency virus (HIV) seropositivity; testing for HIV
             was not required at study entry.

          -  For the purposes of MRI, patients with a pacemaker, ferromagnetic metal implants other
             than those approved as safe for use in MR scanners (eg, some types of aneurysm clips,
             shrapnel), patients suffering from uncontrollable claustrophobia, or those physically
             unable to fit into the machine (eg, obesity).

          -  Patients considered by the investigator as unlikely to be compliant with the study,
             take the study medications, travel for the necessary assessment visits, or have other
             medical conditions likely to interfere with the study assessments.

          -  Patients with another primary malignancy treated within the prior 3 years except
             excised squamous cell carcinomas of the skin and carcinoma in situ lesions of other
             organs which had been treated for cure.

          -  Patients not able to provide reliable informed consent and who did not have a legal
             representative for healthcare decisions on their behalf.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Reardon, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2006</study_first_submitted>
  <study_first_submitted_qc>February 10, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2006</study_first_posted>
  <results_first_submitted>December 20, 2010</results_first_submitted>
  <results_first_submitted_qc>April 20, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 16, 2011</results_first_posted>
  <last_update_submitted>April 20, 2011</last_update_submitted>
  <last_update_submitted_qc>April 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 16, 2011</last_update_posted>
  <responsible_party>
    <name_title>External Affairs</name_title>
    <organization>Novartis</organization>
  </responsible_party>
  <keyword>imatinib mesylate</keyword>
  <keyword>hydroxyurea</keyword>
  <keyword>protein tyrosine kinases</keyword>
  <keyword>glioma</keyword>
  <keyword>glioblastoma multiforme</keyword>
  <keyword>recurrent glioblastoma multiforme</keyword>
  <keyword>GBM</keyword>
  <keyword>MacDonald criteria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
    <mesh_term>Hydroxyurea</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
        <group group_id="P2">
          <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="97"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="95"/>
                <participants group_id="P2" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative problems</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
        <group group_id="B2">
          <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="131"/>
            <count group_id="B2" value="100"/>
            <count group_id="B3" value="231"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="11.9"/>
                    <measurement group_id="B2" value="52.8" spread="11.4"/>
                    <measurement group_id="B3" value="53.3" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With an Objective Overall Response (OOR)</title>
        <description>Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With an Objective Overall Response (OOR)</title>
          <description>Patients with an OOR were those whose best response to treatment was a complete response (CR) or a partial response (PR) assessed with magnetic resonance imaging. A patient had a CR if the target tumors disappeared. A patient had a PR if there was a ≥ 50% reduction in the sum of the products of the largest perpendicular diameters of the target tumors compared to the baseline value. A best response of CR required at least 2 determinations of CR at least 4 weeks apart. A best response of PR required at least 2 determinations of PR or better at least 4 weeks apart (and not qualifying for CR).</description>
          <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" lower_limit="1.3" upper_limit="8.7"/>
                    <measurement group_id="O2" value="3.0" lower_limit="0.6" upper_limit="8.5"/>
                    <measurement group_id="O3" value="3.5" lower_limit="1.5" upper_limit="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Objective Overall Response (OOR)</title>
        <description>Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Objective Overall Response (OOR)</title>
          <description>Duration of OOR only included patients whose best overall response was complete response (CR) or partial response (PR). The start date was the date of the first documented response (CR or PR); the end date was the date of the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, the duration of OOR was censored at the time of the last OOR assessment.</description>
          <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.1" lower_limit="32.1" upper_limit="53.6"/>
                    <measurement group_id="O2" value="32.1" lower_limit="20.1">The upper bound of the confidence interval was non-estimable.</measurement>
                    <measurement group_id="O3" value="37.1" lower_limit="32.1" upper_limit="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Who Had Clinical Benefit</title>
        <description>Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Who Had Clinical Benefit</title>
          <description>Patients who had clinical benefit were patients with a best response of complete response (CR), partial response (PR), or stable disease (SD) lasting for more than 6 months from the start of treatment until the first documented disease progression (PD) or death from any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. SD was defined as insufficient tumor shrinkage to qualify for PR or CR and no increase in lesions which would qualify as PD.</description>
          <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="5.4" upper_limit="16.4"/>
                    <measurement group_id="O2" value="6.0" lower_limit="2.2" upper_limit="12.6"/>
                    <measurement group_id="O3" value="8.2" lower_limit="5.0" upper_limit="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Progression-free Survival at Months 6 and 12</title>
        <description>Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.</description>
        <time_frame>Months 6 and 12</time_frame>
        <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Progression-free Survival at Months 6 and 12</title>
          <description>Progression-free survival (PFS) was defined as the time from the start of treatment to the date of the first documented disease progression (PD) or death due to any cause. (PD) was defined as ≥ 25% increase in size of the sum of the products of the largest perpendicular diameters of the target tumors compared to the smallest value recorded at or after baseline. If a patient had not progressed or died, progression-free survival was censored at the time of the last overall response assessment.</description>
          <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.2" lower_limit="5.7" upper_limit="16.6"/>
                    <measurement group_id="O2" value="9.9" lower_limit="3.8" upper_limit="15.9"/>
                    <measurement group_id="O3" value="10.6" lower_limit="6.5" upper_limit="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" lower_limit="2.4" upper_limit="11.3"/>
                    <measurement group_id="O2" value="3.3" lower_limit="0.0" upper_limit="6.9"/>
                    <measurement group_id="O3" value="5.3" lower_limit="2.3" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients Surviving at Months 6, 12, and 24</title>
        <description>Patients not known to have died were censored at the time of last survival follow-up.</description>
        <time_frame>Months 6, 12, and 24</time_frame>
        <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients Surviving at Months 6, 12, and 24</title>
          <description>Patients not known to have died were censored at the time of last survival follow-up.</description>
          <population>Intent-to-treat (ITT) population: All patients who received at least 1 dose of any of the 2 study drugs.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2" lower_limit="40.7" upper_limit="57.8"/>
                    <measurement group_id="O2" value="50.9" lower_limit="40.9" upper_limit="61.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="43.4" upper_limit="56.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5" lower_limit="20.7" upper_limit="36.2"/>
                    <measurement group_id="O2" value="31.3" lower_limit="21.9" upper_limit="40.7"/>
                    <measurement group_id="O3" value="29.7" lower_limit="23.7" upper_limit="35.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="3.3" upper_limit="18.1"/>
                    <measurement group_id="O2" value="20.3" lower_limit="11.8" upper_limit="28.9"/>
                    <measurement group_id="O3" value="13.9" lower_limit="8.0" upper_limit="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients With at Least 1 Adverse Event</title>
        <description>An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.</description>
        <time_frame>Baseline to end of study (Month 24)</time_frame>
        <population>Safety population: All patients who received at least 1 dose of either of the 2 study drugs and who had at least 1 post-baseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O2">
            <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
          </group>
          <group group_id="O3">
            <title>All Patients - Imatinib 600 or 1000 mg + Hydroxyurea 1000 mg</title>
            <description>Patients took either imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal or imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With at Least 1 Adverse Event</title>
          <description>An adverse event (AE) is any undesirable sign, symptom, or medical condition occurring after starting study drug even if the event is not considered to be related to study drug. Study drug refers to imatinib or hydroxyurea. The study treatment is the combination of these two study drugs.</description>
          <population>Safety population: All patients who received at least 1 dose of either of the 2 study drugs and who had at least 1 post-baseline safety assessment.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="100"/>
                <count group_id="O3" value="231"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The analysis was done on the safety population which consisted of 131 patients in the imatinib 600 mg plus hydroxyurea 1000 mg group and 99 patients in the imatinib 1000 mg plus hydroxyurea 1000 mg group.</desc>
      <group_list>
        <group group_id="E1">
          <title>Imatinib 600 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 600 mg (1 imatinib 400 mg tablet and 2 imatinib 100 mg tablets) orally once daily with the morning meal. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were not allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
        <group group_id="E2">
          <title>Imatinib 1000 mg + Hydroxyurea 1000 mg</title>
          <description>Patients took imatinib 500 mg (1 imatinib 400 mg tablet and 1 imatinib 100 mg tablet) orally twice daily with the morning and evening meals. Patients were instructed to swallow the tablets while drinking a large glass of water. In addition to imatinib, patients took hydroxyurea 500 mg orally twice daily with the morning and evening meals. Patients were allowed concomitant use of enzyme-inducing anticonvulsant drugs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Amaurosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Palatal oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Retroperitoneal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sigmoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Alpha haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumocystis jiroveci pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Septic embolus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Therapeutic agent toxicity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm progression</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cerebral cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Depressed level of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Neurological decompensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tongue biting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Personality change due to a general medical condition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Staring</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchopneumopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="122" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="95" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Cushingoid</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="99"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="99"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862 778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

